SYMPHONY results are valid at the time of
diagnosis. Agendia’s signatures were developed independent of drug
therapy. Thus, the actual test result will indicate the prognosis for
your patient if no therapy is provided. You do not have to assume that
your patient will remain on a course of therapy to validate the test
results. Which makes the SYMPHONY suite of genomic assays the perfect
accompaniment to your current protocols.
The SymphonyTM Personalized Breast Cancer Profile: Agendia
offers a variety of breast cancer assays to help personalize the
patient's treatment by looking at what their likelihood of recurrence
truely is.
- MammaPrint®: The only FDA-cleared Breast Cancer Recurrence Test
- TargetPrint®: Analysis for ER, PR & HER2 Status
- BluePrint™: Molecular Subtyping Profile for Breast Cancer Patients
- TheraPrint®: 56 Therapy Gene Assay
No comments:
Post a Comment